Latest Insider Transactions at Jounce Therapeutics, Inc. (JNCE)
This section provides a real-time view of insider transactions for Jounce Therapeutics, Inc. (JNCE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Jounce Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Jounce Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2023
|
Tang Kevin C Director |
BUY
Other acquisition or disposition
|
Indirect |
10,000
+50.0%
|
$97,370,000
$9737.7 P/Share
|
|
May 03
2023
|
Tang Kevin C Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,300,087
-100.0%
|
$5,300,087
$1.85 P/Share
|
|
May 03
2023
|
Concentra Biosciences, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
10,000
+50.0%
|
$97,370,000
$9737.7 P/Share
|
|
May 03
2023
|
Perry A Karsen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,000
-100.0%
|
-
|
|
May 03
2023
|
Richard /Ca/ Murray Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
188,778
-100.0%
|
-
|
|
May 03
2023
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
66,018
-69.5%
|
-
|
|
May 03
2023
|
Robert Kamen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
33,875
-100.0%
|
-
|
|
May 03
2023
|
Robert Kamen Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
60,975
-100.0%
|
-
|
|
Apr 04
2023
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
39,228
-17.2%
|
$39,228
$1.85 P/Share
|
|
Mar 14
2023
|
Tang Kevin C Director |
BUY
Open market or private purchase
|
Indirect |
20,286
+0.38%
|
$20,286
$1.02 P/Share
|
|
Mar 13
2023
|
Tang Kevin C Director |
BUY
Open market or private purchase
|
Indirect |
65,701
+1.23%
|
$0
$0.99 P/Share
|
|
Jan 10
2023
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
7,781
-10.54%
|
$7,781
$1.12 P/Share
|
|
Jan 10
2023
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
24,879
-9.84%
|
$24,879
$1.12 P/Share
|
|
Jan 10
2023
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,126
-4.72%
|
$5,126
$1.12 P/Share
|
|
Jan 10
2023
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,182
-7.7%
|
$9,182
$1.12 P/Share
|
|
Jan 09
2023
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
6,315
-7.88%
|
$6,315
$1.1 P/Share
|
|
Jan 09
2023
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
20,191
-7.39%
|
$20,191
$1.1 P/Share
|
|
Jan 09
2023
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,159
-3.69%
|
$4,159
$1.1 P/Share
|
|
Jan 09
2023
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,452
-5.88%
|
$7,452
$1.1 P/Share
|
|
Aug 01
2022
|
Hugh M Cole Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+13.63%
|
-
|
|
Feb 01
2022
|
Elizabeth Trehu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+19.61%
|
-
|
|
Feb 01
2022
|
Richard /Ca/ Murray Director |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+24.27%
|
-
|
|
Feb 01
2022
|
Kimberlee C Drapkin President, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+25.55%
|
-
|
|
Feb 01
2022
|
Hugh M Cole Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+28.48%
|
-
|
|
Jan 10
2022
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,205
-8.81%
|
$37,230
$6.65 P/Share
|
|
Jan 10
2022
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
8,222
-13.52%
|
$49,332
$6.65 P/Share
|
|
Jan 10
2022
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
23,924
-11.42%
|
$143,544
$6.65 P/Share
|
|
Jan 10
2022
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,378
-5.94%
|
$32,268
$6.65 P/Share
|
|
Jan 07
2022
|
Hugh M Cole Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,468
-4.69%
|
$24,276
$7.3 P/Share
|
|
Jan 07
2022
|
Kimberlee C Drapkin President, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
4,595
-7.02%
|
$32,165
$7.3 P/Share
|
|
Jan 07
2022
|
Richard /Ca/ Murray Director |
SELL
Open market or private sale
|
Direct |
13,370
-6.0%
|
$93,590
$7.3 P/Share
|
|
Jan 07
2022
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,005
-3.21%
|
$21,035
$7.3 P/Share
|
|
Nov 12
2021
|
Cary Pfeffer Director |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Nov 12
2021
|
Third Rock Ventures Iii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,900,000
-62.32%
|
$15,200,000
$8.38 P/Share
|
|
Sep 15
2021
|
Cary Pfeffer Director |
SELL
Other acquisition or disposition
|
Indirect |
0
|
-
|
|
Sep 15
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,750,000
-39.35%
|
-
|
|
Jun 10
2021
|
Cary Pfeffer Director |
SELL
Other acquisition or disposition
|
Indirect |
0
|
-
|
|
Jun 10
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,500,000
-25.22%
|
-
|
|
May 25
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
552,520
-8.5%
|
$4,420,160
$8.0 P/Share
|
|
Apr 15
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-2.02%
|
$2,000
$10.0 P/Share
|
|
Mar 31
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,300
-8.15%
|
$83,000
$10.09 P/Share
|
|
Mar 31
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,300
+7.53%
|
$33,200
$4.02 P/Share
|
|
Mar 30
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
100
-0.11%
|
$1,000
$10.0 P/Share
|
|
Mar 30
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.11%
|
$400
$4.02 P/Share
|
|
Mar 29
2021
|
Elizabeth Trehu Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,100
-5.17%
|
$51,000
$10.09 P/Share
|
|
Mar 29
2021
|
Elizabeth Trehu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,100
+4.91%
|
$20,400
$4.02 P/Share
|
|
Mar 15
2021
|
John Duncan Higgons Director |
SELL
Open market or private sale
|
Direct |
200
-1.98%
|
$2,400
$12.8 P/Share
|
|
Mar 11
2021
|
Cary Pfeffer Director |
SELL
Other acquisition or disposition
|
Indirect |
0
|
-
|
|
Mar 11
2021
|
Third Rock Ventures Ii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,250,000
-16.13%
|
-
|
|
Mar 01
2021
|
Cary Pfeffer Director |
SELL
Open market or private sale
|
Indirect |
0
|
-
|